These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16942756)

  • 1. Aluminum complexing enhances amyloid beta protein penetration of blood-brain barrier.
    Banks WA; Niehoff ML; Drago D; Zatta P
    Brain Res; 2006 Oct; 1116(1):215-21. PubMed ID: 16942756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copper complexing decreases the ability of amyloid beta peptide to cross the BBB and enter brain parenchyma.
    Mare S; Penugonda S; Robinson SM; Dohgu S; Banks WA; Ercal N
    Peptides; 2007 Jul; 28(7):1424-32. PubMed ID: 17580097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons.
    Clifford PM; Zarrabi S; Siu G; Kinsler KJ; Kosciuk MC; Venkataraman V; D'Andrea MR; Dinsmore S; Nagele RG
    Brain Res; 2007 Apr; 1142():223-36. PubMed ID: 17306234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease.
    Matsumoto Y; Yanase D; Noguchi-Shinohara M; Ono K; Yoshita M; Yamada M
    Dement Geriatr Cogn Disord; 2007; 23(4):241-5. PubMed ID: 17310121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
    LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV
    J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
    Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
    J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.
    Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA
    Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid.
    Englund H; Degerman Gunnarsson M; Brundin RM; Hedlund M; Kilander L; Lannfelt L; Pettersson FE
    Neurodegener Dis; 2009; 6(4):139-47. PubMed ID: 19521063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
    Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
    J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood-brain barrier transport of circulating Alzheimer's amyloid beta.
    Zlokovic BV; Ghiso J; Mackic JB; McComb JG; Weiss MH; Frangione B
    Biochem Biophys Res Commun; 1993 Dec; 197(3):1034-40. PubMed ID: 8280117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier.
    Poduslo JF; Curran GL; Sanyal B; Selkoe DJ
    Neurobiol Dis; 1999 Jun; 6(3):190-9. PubMed ID: 10408808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models.
    van Groen T; Kadish I; Wiesehan K; Funke SA; Willbold D
    ChemMedChem; 2009 Feb; 4(2):276-82. PubMed ID: 19072935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered expression of Abeta metabolism-associated molecules from D-galactose/AlCl(3) induced mouse brain.
    Luo Y; Niu F; Sun Z; Cao W; Zhang X; Guan D; Lv Z; Zhang B; Xu Y
    Mech Ageing Dev; 2009 Apr; 130(4):248-52. PubMed ID: 19150622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aluminum inhibits proteolytic degradation of amyloid beta peptide by cathepsin D: a potential link between aluminum accumulation and neuritic plaque deposition.
    Sakamoto T; Saito H; Ishii K; Takahashi H; Tanabe S; Ogasawara Y
    FEBS Lett; 2006 Dec; 580(28-29):6543-9. PubMed ID: 17112520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.
    Donahue JE; Johanson CE
    J Neuropathol Exp Neurol; 2008 Apr; 67(4):261-70. PubMed ID: 18379441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
    Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of LRP1 [correction of LPR1] at the blood-brain barrier in streptozotocin-induced diabetic mice.
    Hong H; Liu LP; Liao JM; Wang TS; Ye FY; Wu J; Wang YY; Wang Y; Li YQ; Long Y; Xia YZ
    Neuropharmacology; 2009; 56(6-7):1054-9. PubMed ID: 19285094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effect of aluminum on the blood-brain barrier transport of peptides, technetium and albumin.
    Banks WA; Kastin AJ; Fasold MB
    J Pharmacol Exp Ther; 1988 Feb; 244(2):579-85. PubMed ID: 2894456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.
    Wang YJ; Zhou HD; Zhou XF
    Drug Discov Today; 2006 Oct; 11(19-20):931-8. PubMed ID: 16997144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.